Table 1.
Socio-demographics characteristics of the participants (N = 462), lifestyles, co-morbidities, and clinical characteristics of the oncologic disease, at the baseline evaluation, before any treatment, and treatments performed during the first year after breast cancer diagnosis.
| Participants’ and Cancer Characteristics and Treatments | n | % | |
|---|---|---|---|
| Socio-demographics | |||
| Age | |||
| ≥55 years | 230 | 49.8 | |
| Education (years) | |||
| Primary education (≤4) | 194 | 42.0 | |
| Lower secondary education (5–9) | 133 | 28.8 | |
| At least upper secondary education (≥10) | 135 | 29.2 | |
| Living in Greater Porto Area | 207 | 44.8 | |
| Marital status | |||
| Married/living together | 323 | 69.9 | |
| Single | 49 | 10.6 | |
| Widow/divorced | 90 | 19.5 | |
| Professionally active (n = 460) | |||
| Yes | 242 | 52.6 | |
| Monthly income (n = 454) | |||
| Above EUR 500 a | 204 | 44.9 | |
| Lifestyles | |||
| Alcohol consumption > 10 g/day (n = 461) | 92 | 20.0 | |
| Past or current smoker | 96 | 20.8 | |
| Fruits and vegetables ≥ 5/day (n = 459) | 101 | 22.0 | |
| Playing a sport | 80 | 17.3 | |
| Comorbidities | |||
| Hypertension | 146 | 31.6 | |
| Diabetes | 46 | 10.0 | |
| Body Mass Index (kg/m2) | |||
| <18.5 | 5 | 1.1 | |
| 18.5–24.5 | 198 | 43.0 | |
| 25.0–29.9 | 155 | 33.6 | |
| ≥30 | 103 | 22.3 | |
| Chronic medicines consumption | |||
| None | 165 | 35.7 | |
| One | 77 | 16.7 | |
| Two to four | 149 | 32.3 | |
| More than four | 71 | 15.4 | |
| Cancer stage | |||
| 0 | 31 | 6.71 | |
| I | 223 | 48.27 | |
| II | 140 | 30.3 | |
| III | 68 | 14.7 | |
| Breast cancer subtype (n = 433) | |||
| HR+/HER2- | 333 | 76.9 | |
| HER2+ | 64 | 14.8 | |
| Triple negative | 36 | 8.3 | |
| Treatments in the first year | |||
| Breast surgery | |||
| Breast conserving | 235 | 50.9 | |
| Mastectomy | 227 | 49.1 | |
| Axillary surgery | |||
| Sentinel lymph node biopsy | 295 | 65.9 | |
| Axillary lymph node dissection | 153 | 34.1 | |
| Chemotherapy (n = 279) | |||
| Neoadjuvant | 30 | 10.8 | |
| Adjuvant | 249 | 89.2 | |
| Taxane-based | 198 | 71.0 | |
| Radiotherapy | |||
| Yes | 341 | 73.8 | |
| Endocrine therapy | |||
| Yes | 388 | 84.0 | |
| Targeted therapy | |||
| Yes | 61 | 13.2 | |
a EUR500 is the median value of monthly income in the sample. HR+/HER2 stands for tumor expressing hormone receptor but not overexpressing human epidermal growth factor receptor 2; HER2+ stands for tumor overexpressing HER2; triple negative stands for tumor not expressing estrogen receptors, nor progesterone receptors, nor overexpressing HER2.